WDA(H) Guide
WDA(H) vs MAH: Key Differences for UK Pharmaceutical Businesses
This article explains the difference in plain English so UK pharmaceutical businesses can understand which responsibilities sit where and where quality agreements are needed.
WDA(H) and MAH are often discussed together, but they are not the same thing. A WDA(H) supports wholesale distribution activities, while a Marketing Authorisation Holder is linked to the product authorisation for placing a medicine on the market.
The short version
A WDA(H) holder is authorised for wholesale distribution of human medicines and must operate in line with GDP. A MAH holds the marketing authorisation for a medicinal product and is accountable for the authorised product being placed on the market under the relevant authorisation.
A business can be one, both or neither, depending on its role. The key is to avoid assuming another party owns a control unless it is clearly assigned and evidenced.
What the WDA(H) holder controls
The WDA(H) holder controls authorised wholesale distribution activities: premises, storage, transport, supplier/customer qualification, returns, recalls, complaints, deviations, training, self-inspections and Responsible Person oversight.
The WDA(H) holder should be able to show that the product has remained within a controlled GDP supply chain.
What the MAH controls
The MAH is linked to the marketing authorisation for the product. In a practical quality system, MAH oversight often includes product quality interfaces, supply-chain decisions, quality agreements, product information and escalation of quality defects or recalls.
The MAH may outsource activities, but outsourcing should not create ambiguity about accountability.
Where roles overlap
Overlap usually appears around complaints, recalls, product quality defects, temperature excursions, returned goods, distribution changes and third-party providers. These are the areas where weak quality agreements create real operational risk.
A good agreement explains who detects, assesses, escalates, approves and documents each event.
How to decide what support you need
If you distribute medicines, WDA(H) and GDP readiness should be reviewed. If you hold or support a marketing authorisation, MAH quality and supply-chain oversight should be reviewed. If several parties are involved, Contract QA can help define the interfaces before an issue occurs.
Official sources used
How SwiftGxP can help
If you need practical QA support, I can help with:
- WDA(H) and MAH responsibility mapping
- Quality agreement review
- GDP gap assessments and supplier oversight
- Contract QA for outsourced quality interfaces
Important regulatory note
General guidance only
This WDA(H) and MAH responsibilities article is general guidance and is not regulatory advice. It should not be relied on as specific advice for your organisation.
GDP, WDA(H) and Responsible Person expectations can vary depending on your authorised activities, site arrangements, suppliers, products and quality system. If you need advice for your circumstances, please get in touch with Miglė to discuss your requirements.
Ask Miglė for specific advice